Edgewise Therapeutics, Inc.

NasdaqGS:EWTX Stock Report

Market Cap: US$2.8b

Edgewise Therapeutics Future Growth

Future criteria checks 0/6

Edgewise Therapeutics is forecast to grow earnings and revenue by 0.06% and 84% per annum respectively. EPS is expected to grow by 4.4% per annum. Return on equity is forecast to be -34.2% in 3 years.

Key information

0.06%

Earnings growth rate

4.4%

EPS growth rate

Pharmaceuticals earnings growth24.0%
Revenue growth rate84.0%
Future return on equity-34.2%
Analyst coverage

Good

Last updated19 Dec 2024

Recent future growth updates

Recent updates

Here's Why We're Not Too Worried About Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Situation

Nov 26
Here's Why We're Not Too Worried About Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Situation

Edgewise: Stock Is Bouncing On Heart Disease Drug Data, Albeit From Just 7 Patients (Rating Upgrade)

Sep 19

We Think Edgewise Therapeutics (NASDAQ:EWTX) Can Afford To Drive Business Growth

Aug 12
We Think Edgewise Therapeutics (NASDAQ:EWTX) Can Afford To Drive Business Growth

Edgewise Therapeutics: Strong Open Label Data Makes For A Bullish Signal

Aug 05

Edgewise: Intriguing Drug Candidate, But Consider Selling After Recent Run

May 10

We're Not Very Worried About Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Rate

May 10
We're Not Very Worried About Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Rate

Edgewise Therapeutics: Behind The Massive Rally

Feb 18

Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth

Dec 07
Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth

Edgewise Therapeutics (NASDAQ:EWTX) Is In A Good Position To Deliver On Growth Plans

Aug 16
Edgewise Therapeutics (NASDAQ:EWTX) Is In A Good Position To Deliver On Growth Plans

Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth

Apr 28
Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth

We Think Edgewise Therapeutics (NASDAQ:EWTX) Can Afford To Drive Business Growth

Jan 13
We Think Edgewise Therapeutics (NASDAQ:EWTX) Can Afford To Drive Business Growth

Edgewise Therapeutics proposes $100M stock offering plan

Sep 13

Edgewise Therapeutics GAAP EPS of -$0.32 beats by $0.02

Aug 04

Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth

Aug 02
Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth

We're Hopeful That Edgewise Therapeutics (NASDAQ:EWTX) Will Use Its Cash Wisely

Mar 24
We're Hopeful That Edgewise Therapeutics (NASDAQ:EWTX) Will Use Its Cash Wisely

We're Hopeful That Edgewise Therapeutics (NASDAQ:EWTX) Will Use Its Cash Wisely

Nov 23
We're Hopeful That Edgewise Therapeutics (NASDAQ:EWTX) Will Use Its Cash Wisely

Edgewise Therapeutics names new chief medical officer

Apr 27

Earnings and Revenue Growth Forecasts

NasdaqGS:EWTX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202610-205N/A-2366
12/31/2025N/A-175-121-1397
12/31/2024N/A-131-94-1057
9/30/2024N/A-124-110-109N/A
6/30/2024N/A-116-105-104N/A
3/31/2024N/A-106-99-98N/A
12/31/2023N/A-100-98-92N/A
9/30/2023N/A-89-86-77N/A
6/30/2023N/A-81-77-67N/A
3/31/2023N/A-76-72-63N/A
12/31/2022N/A-68-58-53N/A
9/30/2022N/A-61-53-50N/A
6/30/2022N/A-56-48-46N/A
3/31/2022N/A-51-41-40N/A
12/31/2021N/A-43-34-34N/A
9/30/2021N/A-36-29-29N/A
6/30/2021N/A-27-24-24N/A
3/31/2021N/A-21-18-18N/A
12/31/2020N/A-17-15-15N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: EWTX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: EWTX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: EWTX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: EWTX is forecast to have no revenue next year.

High Growth Revenue: EWTX is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: EWTX is forecast to be unprofitable in 3 years.


Discover growth companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 07:44
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Edgewise Therapeutics, Inc. is covered by 9 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Cory KasimovEvercore ISI
Madhu KumarGoldman Sachs
Paul ChoiGoldman Sachs